Video
Next Steps in Assessing BOVen Therapy in Patients With Previously Untreated CLL
Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.
Pharmacy Times interviewed Jacob D. Soumerai, MD, assistant professor, medicine at Harvard Medical School and a clinical investigator in lymphoma, medicine at Massachusetts General Hospital, on his recent presentation at the American Society of Hematology Annual Meeting and Exposition 2021 on minimum residual disease-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated chronic lymphocytic leukemia (CLL).
During this discussion, Soumerai goes over the next steps in the research assessing the safety and efficacy of BOVen in patients with previously untreated CLL following the phase 2 trial results.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa
